Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia
Latest Information Update: 09 May 2022
At a glance
- Drugs Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 16 Jun 2008 New trial record.